Vanda Pharmaceuticals: Promising Revenue Growth and Strategic Pipeline Drive Buy Rating
PremiumRatingsVanda Pharmaceuticals: Promising Revenue Growth and Strategic Pipeline Drive Buy Rating
2M ago
Vanda Pharmaceuticals price target raised to $20 from $18 at H.C. Wainwright
Premium
The Fly
Vanda Pharmaceuticals price target raised to $20 from $18 at H.C. Wainwright
2M ago
Vanda Pharmaceuticals’ Earnings Call: Mixed Results and Future Optimism
Premium
Company Announcements
Vanda Pharmaceuticals’ Earnings Call: Mixed Results and Future Optimism
2M ago
Vanda’s Strategic In-Licensing of Imsidolimab Signals Promising Growth in GPP Market
PremiumRatingsVanda’s Strategic In-Licensing of Imsidolimab Signals Promising Growth in GPP Market
2M ago
AnaptysBio, Vanda announce exclusive global license agreement for Vanda
Premium
The Fly
AnaptysBio, Vanda announce exclusive global license agreement for Vanda
2M ago
Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab
Premium
The Fly
Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab
2M ago
Vanda Pharmaceuticals: Orphan Drug Designation Granted for VGT-1849A
PremiumThe FlyVanda Pharmaceuticals: Orphan Drug Designation Granted for VGT-1849A
4M ago
Vanda Pharmaceuticals treatment of polycythemia vera granted orphan status
Premium
The Fly
Vanda Pharmaceuticals treatment of polycythemia vera granted orphan status
4M ago
Vanda Pharmaceuticals Reports Strong Q3 2024 Growth
Premium
Company Announcements
Vanda Pharmaceuticals Reports Strong Q3 2024 Growth
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100